Insulet Strategy and Business Model

Executive Overview

Insulet is a diabetes-device company best known for Omnipod, its tubeless wearable insulin-delivery platform. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet operates at the intersection of medical devices, diabetes software, and recurring consumables. Its flagship product, Omnipod 5, is an automated insulin delivery system that combines a disposable Pod worn on the body with control software and compatible continuous glucose monitoring integrations. Strategically, Insulet is trying to expand insulin-pump adoption beyond the traditional pump market by making therapy easier to start, easier to wear, and easier to access through the pharmacy channel. That matters because many insulin users still rely on multiple daily injections rather than pumps. The United States remains Insulet’s largest market, but the company is also expanding across Europe, Canada, the Middle East, Australia, and other selected international markets. Economically, Insulet benefits from a repeat-driven model because Pods must be replaced regularly by active users. By FY2024, annual revenue had moved above $2 billion, reflecting growth in Omnipod 5 adoption, international rollout, and continued manufacturing scale-up.

Insulet at a Glance

Logo
Common name	Insulet
Full legal name	Insulet Corporation
Headquarters	Acton, Massachusetts, United States
Ownership	Public company; broadly held institutional ownership
Ticker	PODD
Exchange	NASDAQ
Market Cap	$9.96B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2000; initial Omnipod commercialization in the mid-2000s; initial public offering in 2007; Omnipod DASH launched in the late 2010s; Omnipod 5 U.S. launch in 2022
Industry or industries	Medical devices; diabetes management technology
Key products or services	Omnipod 5, Omnipod DASH, Omnipod GO, disposable Pods, controllers, diabetes software, training and support
Geographic footprint	United States, Europe, Canada, Middle East, Australia, and other selected international markets
Business segments as officially reported	One operating and reportable segment focused on insulin-delivery systems
Company website	https://www.insulet.com

1. What Is the Strategy of Insulet?

Insulet’s public materials consistently point to a focused growth strategy: expand use of insulin-pump therapy by making it simpler and more convenient, then monetize that installed base through recurring Pod sales. Using the Playing to Win framework, the strategy can be summarized as follows.

1. 1a. What is the winning aspiration of Insulet?

   Insulet’s winning aspiration is to make Omnipod the preferred insulin-delivery platform for a broader population of insulin users than traditional tethered pumps have historically served. In practical terms, that means improving outcomes and quality of life for people with diabetes while also expanding the addressable market for pump therapy. The company’s public messaging emphasizes simplification, freedom from tubing, and broader access rather than serving only the most experienced pump users.

   Management has also framed success in economic terms: grow the active user base, increase recurring Pod utilization, expand internationally, and improve profitability through manufacturing scale. Insulet does not rely on a single public market-share target in its core filings, but its strategy clearly aims at category expansion, not just share shifts within the existing pump market.

2. 1b. Where does Insulet play?

   Insulet plays in insulin-delivery systems for people who require insulin therapy, especially those with type 1 diabetes and other insulin-intensive forms of diabetes. Its current field of play includes tubeless patch-pump therapy, automated insulin delivery, and adjacent type 2 opportunities. Geographically, the company plays first and foremost in the United States, while expanding into selected international markets where reimbursement, regulatory approvals, and commercial economics are attractive.

   It also chooses to play through channels that can reduce friction for users, especially the pharmacy channel in the United States. That is strategically important because access mechanics can be as important as product features in diabetes technology adoption.

3. 1c. How does Insulet plan to win?

   Insulet plans to win through differentiation, not cost leadership. Its core value proposition is a tubeless, wearable insulin-delivery experience designed to be simpler and more lifestyle-friendly than traditional pump systems. Omnipod 5 adds automated insulin-delivery capabilities, which strengthens the clinical and convenience case. The company also appears to believe that easier access through pharmacy channels can make Omnipod more approachable than pump models that depend more heavily on durable medical equipment pathways.

   Another important part of the recipe is market expansion. Insulet is not only trying to take share from other pump makers; it is trying to convert people who still use multiple daily injections and may have viewed pumps as too burdensome.

4. 1d. What capabilities must Insulet have in place?

   To execute this strategy, Insulet needs a tightly linked set of capabilities:

   • Device and software innovation in patch-pump design, algorithm-enabled delivery, and user experience
   • Clinical, regulatory, and quality capabilities to win approvals and maintain patient safety in a highly regulated category
   • High-volume manufacturing and supply-chain execution, because recurring Pod demand is only attractive if the company can produce reliably and at scale
   • Reimbursement and market-access expertise, especially with pharmacy benefit structures and international payer systems
   • Customer onboarding, training, and support capabilities for patients and healthcare professionals
   • Interoperability and partnership management with continuous glucose monitoring ecosystem partners

5. 1e. What management systems does Insulet require?

   Insulet requires management systems that reinforce both medical-device discipline and recurring-revenue discipline. On the medical-device side, that includes design controls, manufacturing quality systems, complaint handling, post-market surveillance, cybersecurity, and regulatory compliance. On the recurring-revenue side, it needs strong metrics around new patient starts, Pod refill retention, channel inventory, gross margin, manufacturing yields, and customer-support responsiveness.

   Because launches are country-specific and reimbursement-dependent, Insulet also needs robust launch governance, demand planning, and capital-allocation systems. If any of those systems weaken, the business can feel the impact quickly through slower starts, lower refill consistency, or higher manufacturing cost per Pod.

2. What Are the Current Strategic Initiatives of Insulet?

Based on recent annual-report, earnings-call, and investor-presentation themes through FY2024, Insulet’s current strategic initiatives are concentrated in a handful of highly specific areas.

• Drive broader Omnipod 5 adoption in the United States.
  Insulet has been focused on increasing new customer starts, converting legacy Omnipod users onto Omnipod 5, and broadening use among patients who previously relied on injections. This is both a revenue initiative and a category-expansion initiative.
• Expand Omnipod 5 internationally, market by market.
  International expansion requires regulatory clearance, reimbursement work, physician education, customer support buildout, and country-by-country launch sequencing. Insulet’s public strategy has been to deepen its footprint in selected markets rather than pursue indiscriminate geographic spread.
• Scale manufacturing capacity and improve gross margin.
  Insulet has invested in automated manufacturing capacity, especially in Malaysia, to support higher Pod volumes and improve production economics. This matters because the business model becomes more attractive as the installed base rises and unit manufacturing costs improve.
• Broaden ecosystem interoperability and user convenience.
  Publicly disclosed development priorities have included additional continuous glucose monitor integrations and broader mobile-control capabilities. These features matter because they improve user experience and can reduce friction in adoption.
• Expand into the larger type 2 opportunity.
  Insulet has publicly discussed the large population of insulin-using people with type 2 diabetes who are not on pumps. Initiatives tied to that opportunity include dedicated offerings such as Omnipod GO, evidence generation, and commercial work to reach prescribers beyond the traditional endocrinology base.
• Strengthen payer and channel access.
  In diabetes devices, reimbursement is strategy. Insulet has continued to emphasize pharmacy access, formulary coverage, and channel execution because product demand alone does not guarantee uptake.

3. What Is the Business Model of Insulet?

Insulet’s business model is best understood as a recurring consumables model built on a wearable medical device platform. The company does not sell insulin; it sells the delivery system that administers insulin. Economically, the most important sale is not the initial hardware. It is the repeat purchase of Pods over the life of an active user.

• What customers actually buy:
  Patients typically start with access to the Omnipod system, then purchase or receive ongoing supplies of disposable Pods. Controllers, compatible app access, training, and support are part of the broader offering.
• Recurring versus one-time revenue:
  The large economic engine is recurring or repeat-driven. Pods must be replaced regularly, usually every few days, so an active user generates ongoing replenishment demand. Initial hardware and onboarding revenue are much more one-time in nature.
• Revenue model:
  This is not a software subscription model. It is a medical-device consumables model sold through pharmacy, durable medical equipment, and international channels. Once a patient is trained and retained, revenue behaves in a highly repeatable way.
• Pricing power:
  Insulet has some pricing power through differentiation, clinical utility, convenience, and switching frictions. But pricing is constrained by payers, reimbursement contracts, competitive alternatives, and national health systems in many international markets.
• Why business mix matters:
  A larger installed base of active users improves visibility and supports recurring sales. Mix also matters because different geographies, channels, and product generations can carry different margin profiles.
• What drives gross margin, operating margin, and cash generation:
  Gross margin is driven mainly by manufacturing scale, yields, material costs, freight, startup costs for new lines, and product mix. Operating margin depends on how efficiently Insulet scales sales, marketing, support, and research and development spending relative to Pod growth. Cash generation benefits from recurring Pod sales but can be held back by inventory needs and capital spending for capacity expansion.

That combination makes Insulet structurally attractive when execution is strong: each incremental user can become a multiyear stream of refill revenue, provided the company maintains product reliability, reimbursement access, and patient satisfaction.

4. What Products and/or Services Does Insulet Sell?

Insulet is overwhelmingly an Omnipod company. Its most important offerings are all tied to insulin delivery.

• Omnipod 5.
  This is Insulet’s flagship product and the strategic center of the company. It is an automated insulin-delivery system designed to adjust insulin delivery using continuous glucose monitoring data and control software. For growth, competitive positioning, and patient adoption, this is the most important product in the portfolio.
• Omnipod DASH.
  DASH is an earlier Omnipod generation that remains relevant in certain geographies, transition periods, or customer situations. Strategically, it is more of a legacy or bridge platform than the main growth engine.
• Omnipod GO.
  Insulet has publicly introduced Omnipod GO as a basal-only wearable insulin-delivery offering aimed at part of the type 2 population. It is strategically important because it speaks to a much larger market than the traditional pump category, even if it is not yet the core revenue driver.
• Pods, controllers, accessories, and support.
  The Pods are the economic heart of the model. Controllers and related accessories matter, but recurring Pod demand is what drives most of the business value. Training, customer support, and digital experience are also part of the overall service package because diabetes technology adoption depends on successful onboarding and ongoing use.

In short, Omnipod 5 appears to drive the greatest strategic importance, while recurring Pod sales drive the most durable economic value.

5. What Are the Key Competitors or Peers of Insulet?

Insulet competes most directly with other insulin-pump and automated insulin-delivery companies, but its broader substitute set includes injection-based therapy. That is important because one of Insulet’s strategic goals is to convert people who are not using pumps today.

Dexcom and Abbott are important ecosystem partners rather than direct competitors, because their continuous glucose monitoring systems can be integral to automated insulin-delivery workflows.

6. What Is the Marketing Strategy of Insulet?

Insulet’s marketing strategy appears to blend medical-device education with consumer-influenced brand marketing. That hybrid approach fits the category: Omnipod is prescribed and reimbursed like a medical product, but the purchase decision is strongly influenced by comfort, wearability, lifestyle fit, and patient preference.

• Brand marketing:
  The Omnipod brand is important because tubeless wearability is highly visible to patients and caregivers. Brand positioning is tied to simplicity, freedom of movement, and a less cumbersome user experience.
• Healthcare-professional marketing:
  Prescribers, diabetes educators, and clinic staff are critical gatekeepers. Training and clinical education are therefore central, especially when new automated-insulin-delivery capabilities are introduced.
• Performance and digital marketing:
  Because patients often research devices before speaking with clinicians, digital lead generation and education likely play an important role in moving prospective users into the funnel.
• Channel and access marketing:
  Messaging to payers, pharmacies, and reimbursement stakeholders is strategically important. In this category, easier access can be as persuasive as a new feature.

Marketing is not the sole source of competitive advantage for Insulet; product design, clinical performance, and reimbursement access matter more. But effective marketing amplifies those strengths and helps category expansion.

7. What Are the Key Customer Segments of Insulet?

Insulet serves a multilayered customer base. The end user is the patient, but prescribing clinicians, payers, and channel partners all influence adoption.

• People with type 1 diabetes.
  This is the core customer segment and historically the center of pump adoption.
• People with insulin-intensive type 2 diabetes.
  This is the most important growth segment. It is much larger than the traditional pump population, but it is also more heterogeneous and often requires a different commercial approach.
• Pediatric and caregiver-driven households.
  Ease of use, safety, and wearability are especially important here, making Omnipod’s tubeless design commercially relevant.
• Prescribers and diabetes-care professionals.
  Endocrinologists are important, but primary care can become more relevant if Insulet expands deeper into type 2. Diabetes educators and clinic staff also influence onboarding success.
• Payers, pharmacy benefit managers, national health systems, and channel intermediaries.
  These stakeholders are not the end users, but they strongly shape access, switching, and affordability.

Insulet is diversified across age groups and payer types, but the company is still meaningfully concentrated in diabetes and, within that, in insulin-using populations. The U.S. market remains the largest contributor.

8. What Is the Sales Model of Insulet?

Insulet’s sales model combines direct commercial engagement with channel-based fulfillment. The company does not operate like a pure consumer e-commerce business or like a hospital capital-equipment vendor. It sells into a reimbursement-driven care pathway.

• Direct commercial selling to clinicians and accounts:
  Insulet uses sales, clinical, and field-support resources to educate prescribers, clinics, and diabetes educators. That helps drive new patient starts and conversions.
• Pharmacy channel in the United States:
  This is a strategic channel for Insulet because it can lower friction, reduce upfront barriers, and make replenishment easier. It also changes the cadence of revenue toward refill-driven activity.
• Durable medical equipment and other reimbursement pathways:
  Some users still come through traditional medical-device channels, depending on payer structure and market conditions.
• International direct and distributor mix:
  In larger or more strategic countries, Insulet may support sales more directly; in smaller markets, distributors can play a larger role.
• Customer support and onboarding:
  In diabetes technology, the “sale” is incomplete until the user is trained, activated, and reliably reordering Pods. Support functions are therefore part of the sales model, not just post-sale overhead.

This channel structure affects growth and pricing. Pharmacy access can support faster adoption and better refill continuity, while country-specific reimbursement and distributor structures can affect pricing power and market speed. It also creates useful consulting opportunities around channel mix, patient onboarding, refill retention, and field-force effectiveness.

9. In What Geographies Does Insulet Operate?

Insulet operates globally, but its footprint is still anchored in the United States. The company sells to customers in the U.S. and in selected international markets across Europe, Canada, the Middle East, Australia, and other regions where it has secured the necessary regulatory and reimbursement infrastructure.

From an operating-footprint perspective, the most important disclosed hubs include:

• Acton, Massachusetts: headquarters, corporate leadership, research and development, and key support functions
• Malaysia: a major manufacturing hub for Pod production and a central element of Insulet’s scale and margin strategy
• Commercial teams across the United States and selected international markets: supporting launch execution, market access, and customer support

Geographically, the company is still more concentrated than a diversified multinational medtech giant. That concentration is not unusual for a focused diabetes-device company, but it means U.S. reimbursement dynamics and international launch sequencing remain especially important to performance.

10. Who Are the Owners of Insulet?

Insulet is a publicly traded company listed on Nasdaq under the ticker PODD. As of the latest proxy-era public ownership disclosures, Insulet did not have a controlling shareholder. Ownership was dominated by large institutional investors, with firms such as The Vanguard Group, BlackRock, and State Street among the notable holders. As with most public companies, those ownership positions are time-sensitive and can change quarter to quarter.

11. How Is Insulet Organized?

Officially, Insulet reports as a single operating and reportable segment centered on insulin-delivery systems. That is important: while the company sells several product variants, investors should think of Insulet as one focused diabetes-platform business rather than a multi-division conglomerate.

At a practical level, the company appears to be organized around:

• Product development, clinical, regulatory, and quality functions
• Manufacturing, supply chain, and operations
• U.S. commercial and market-access teams
• International commercial teams
• Corporate functions such as finance, legal, human resources, and information technology

Within that structure, Omnipod is the umbrella platform, while specific offerings such as Omnipod 5, DASH, and GO sit underneath it. The management structure therefore looks simpler than the product surface might suggest.

12. How Does Insulet Operate?

Day to day, Insulet operates as a regulated medical-device manufacturer with a recurring-consumables engine. Its value creation depends on far more than product design alone.

• Design, clinical, and regulatory work:
  Insulet develops hardware, software, algorithms, and human-factors improvements, then validates them through a regulated product-development process.
• Component sourcing and manufacturing:
  The company procures specialized materials and components, runs automated production lines, and manages quality-control processes for large volumes of Pods and related hardware.
• Commercial access and fulfillment:
  Insulet secures reimbursement, works with pharmacy and other channels, and ensures product availability to active users whose therapy depends on timely resupply.
• Training and support:
  Onboarding, troubleshooting, and customer care are essential because therapy adherence and refill continuity depend on users being comfortable with the system.
• Post-market quality and software maintenance:
  As with other connected medtech products, Insulet must monitor reliability, complaint trends, software performance, and cybersecurity risks.

The operational complexity is significant. A supply disruption, quality issue, or delayed rollout can affect not just sales, but therapy continuity for existing users. That gives manufacturing discipline and service execution unusually high strategic importance.

13. What Are the Growth Opportunities for Insulet?

Insulet’s most plausible growth opportunities are visible in public company materials and in the structure of the diabetes market.

• Further penetration of the type 1 pump market.
  Insulet can continue winning new users from other pump systems and from injection therapy, especially where tubeless wearability is a strong differentiator.
• Expansion into insulin-using type 2 diabetes.
  This is the largest strategic upside. The type 2 population is much larger than the legacy pump market, but reaching it requires simpler workflows, broader prescriber coverage, and strong payer support.
• International rollout.
  Many markets remain earlier in their Omnipod 5 adoption curve than the United States. Country-by-country expansion offers both revenue growth and installed-base growth for recurring Pod demand.
• Additional interoperability and user-experience improvements.
  More seamless phone control, more sensor integrations, and easier onboarding can improve conversion and retention.
• Margin expansion through scale.
  Growth does not have to come only from more users. Higher manufacturing utilization and better yields can improve the economics of the installed base.
• Broader prescriber reach.
  If Insulet can extend its commercial model beyond endocrinology into appropriate primary-care and type 2 pathways, its addressable market could expand materially.

The main constraints are also clear: reimbursement limits, regulatory timelines, manufacturing execution, competition, dependence on ecosystem compatibility, and the complexity of educating a broader prescriber base.

14. What Is the History of Insulet?

Insulet was founded in 2000 in Massachusetts with the goal of simplifying insulin-pump therapy through a tubeless design. The company commercialized the original Omnipod in the mid-2000s, establishing a differentiated position in a pump market that had long been dominated by tethered systems.

• 2000: Insulet is founded.
• Mid-2000s: Original Omnipod platform reaches the market and begins establishing the company in diabetes technology.
• 2007: Insulet becomes a public company through its initial public offering.
• Late 2010s: Omnipod DASH broadens the platform and updates the user experience.
• 2022: Omnipod 5 launches in the United States, marking Insulet’s move deeper into automated insulin delivery.
• 2023-FY2024: The company continues international expansion of Omnipod 5 and scales manufacturing capacity, especially in Malaysia.

Unlike some medtech companies, Insulet’s story is not primarily one of serial acquisitions. Its history is more about platform evolution, operational improvement, and category expansion around a single flagship franchise.

15. What Are the Key Suppliers to Insulet?

Suppliers matter to Insulet because the company sells a high-volume, safety-critical disposable device. Public filings do not provide a simple ranked supplier roster, but the strategically important supplier categories are clear.

• Medical-grade plastics, adhesives, and packaging materials used in Pods and related components
• Electronics, sensors, batteries, and other precision components used in controllers and Pod functionality
• Cannula, pumping, and fluid-path components that must meet strict quality and reliability standards
• Manufacturing equipment and automation suppliers that influence throughput, yield, and cost per Pod
• Logistics and distribution partners that help keep refill product available to active users

Insulet’s interoperability partners, including continuous glucose monitoring companies, are not suppliers in the narrow component sense, but they are strategically critical to the Omnipod 5 ecosystem. Supplier structure matters because any bottleneck, qualification delay, or component-quality issue can disrupt both growth and continuity of care.

16. What Are the Key Brands Owned by Insulet?

Branding is important to Insulet because patients wear the product continuously and often choose it based on both lifestyle fit and therapy performance. Insulet’s brand architecture is relatively focused.

• Omnipod.
  The core master brand. It stands for tubeless insulin delivery and is the company’s most important commercial asset.
• Omnipod 5.
  The flagship sub-brand associated with automated insulin delivery. This is the product most tied to current growth and innovation.
• Omnipod DASH.
  A legacy or transitional sub-brand that remains part of the installed base and product continuum.
• Omnipod GO.
  A newer sub-brand aimed at expanding Insulet’s reach into part of the type 2 market.

Insulet is not a multi-brand consumer-products company. Its strategy is more focused: build a powerful platform brand and extend it across adjacent use cases.

17. How Does the Supply Chain of Insulet Function?

Insulet’s supply chain is strategically important because the company must reliably deliver large volumes of disposable Pods to active users whose therapy depends on uninterrupted resupply.

• Sourcing:
  The company procures specialized components and materials from qualified suppliers, often under strict regulatory and quality requirements.
• Manufacturing:
  Pods are produced on automated lines, with manufacturing scale and yield improvement central to cost structure. Malaysia has become a major node in that network.
• Inventory and planning:
  Demand planning matters because user growth, international launches, and reimbursement changes can alter order patterns. Underbuilding inventory risks product shortages; overbuilding ties up cash.
• Distribution:
  Finished goods move through pharmacy, other reimbursement channels, and international distribution structures before reaching patients.
• Service logistics:
  Because users depend on frequent replenishment, customer service, replacements, and issue resolution are part of supply-chain performance, not separate from it.

For Insulet, supply-chain reliability is not just a cost issue. It is a patient-experience issue, a reimbursement issue, and a brand-trust issue.

18. What Is the Technology Strategy of Insulet?

Technology is central to Insulet’s competitiveness. The company is not only a device maker; it is building a connected insulin-delivery platform whose value depends on hardware, software, interoperability, and data-driven control.

• Customer-facing technology:
  Insulet’s core technology strategy revolves around the tubeless Pod architecture, automated insulin-delivery software, mobile control, and compatibility with external continuous glucose monitoring systems.
• Ecosystem strategy:
  Interoperability matters because users want flexibility and because sensor compatibility can influence adoption. Publicly disclosed development work has included broadening compatible ecosystem options.
• Internal technology enablement:
  Manufacturing automation, quality systems, data analytics, and software maintenance are important internal enablers of scale and reliability.
• Cybersecurity and regulated software discipline:
  As Omnipod becomes more connected and app-driven, software quality and cybersecurity become more central to trust and regulatory compliance.

Insulet’s technology strategy is notable because technology is both part of the customer offering and a core operational enabler. That dual role raises the strategic importance of engineering execution.

19. What Is the R&D Strategy of Insulet?

Research and development is a major strategic lever for Insulet. The company’s R&D work appears focused on four linked goals: improving automated insulin delivery, expanding interoperability, broadening the eligible patient population, and increasing ease of use. In a company like Insulet, innovation is not only about breakthrough science; it is also about human factors, wearability, reliability, app experience, and clinical evidence.

Publicly visible R&D priorities have included next-generation Omnipod capabilities, software and mobile enhancements, additional continuous glucose monitor integrations, and work that supports expansion into broader diabetes populations, including type 2. Clinical studies and regulatory submissions are part of that R&D system because new features and indications require evidence. Insulet also appears to invest in manufacturing engineering, which is strategically important because product design choices and production economics are tightly linked in a disposable-device model.

20. What Is the Finance Strategy of Insulet?

Insulet’s finance strategy appears oriented toward reinvestment and scale rather than near-term cash distribution. The company has historically prioritized capital allocation toward manufacturing capacity, product development, international expansion, and commercial execution. That fits the underlying economics: the installed base becomes more valuable as recurring Pod revenue grows, so spending that supports new user starts and reliable supply can create long-lived value.

Several financial themes stand out. First, gross-margin improvement is strategically important because manufacturing scale and yields can materially lift profitability in a consumables model. Second, operating leverage depends on balancing growth investment in sales, support, and R&D against the repeat revenue from existing users. Third, working capital and capital expenditures matter because rapid growth requires inventory, production capacity, and launch readiness. Insulet has not been managed like a dividend story; it has been managed like a focused growth medtech company trying to widen a recurring-revenue platform.

21. How Companies Like Insulet Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants in over 50 countries, including alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Insulet use Umbrex when they need senior problem-solving talent with top-tier training, but do not need a full consulting team with the overhead of a large firm. Umbrex consultants span strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a company like Insulet, the most valuable projects are usually the ones tied directly to category expansion, operational scale, and launch execution.

• U.S. type 2 diabetes market-entry strategy for Omnipod GO or other simplified insulin-delivery pathways
• International launch sequencing and country prioritization for Omnipod 5, including reimbursement readiness and commercial model design
• Pharmacy-versus-durable-medical-equipment channel optimization, including economics, refill retention, and payer access tradeoffs
• Manufacturing footprint and capacity-planning strategy for Pod volume growth, including cost-to-serve and gross-margin improvement opportunities
• Sales-force effectiveness work for endocrinology, diabetes educators, and expansion into broader prescriber segments
• Customer onboarding and service redesign to improve activation, training completion, and long-term Pod utilization
• Supply-chain resilience and sales-and-operations-planning improvement for a high-volume recurring consumables business
• Pricing, reimbursement, and market-access analytics for new geographies or new patient populations
• Technology roadmap support for ecosystem partnerships, mobile strategy, and digital operating model design
• Finance and performance-management projects such as margin bridge analysis, capital-allocation planning, and KPI redesign for a recurring-device model